J A Copland - JoVE Visualize

Showing results (21-30 of 29) with videos related to

Pageof 3

Sort By:

You have reached the last page of results.This site can display upto 29 results.

The Journal of Steroid Biochemistry and Molecular Biology|June 1, 1994

Design of novel antiestrogensL B Hendry, C K Chu, M L Rosser, et al.

Genes & Cancer|September 10, 2010

Expression of the PAX8/PPARγ Fusion Protein Is Associated with Decreased Neovascularization In Vivo: Impact on Tumorigenesis and Disease PrognosisH V Reddi, P Madde, L A Marlow, et al.

Neuropeptides|December 1, 1996

Molecular cloning and functional characterization of the oxytocin receptor from a rat pancreatic cell line (RINm5F)Y J Jeng, S J Lolait, Z Strakova, et al.

The Journal of Steroid Biochemistry and Molecular Biology|October 1, 1993

Inhibition of estrogen stimulated mitogenesis by 3-phenylacetylamino-2,6-piperidinedione and its para-hydroxy analogJ A Copland, L B Hendry, C K Chu, et al.

Cell Proliferation|May 29, 2007

Directed engineering of umbilical cord blood stem cells to produce C-peptide and insulinL Denner, Y Bodenburg, J G Zhao, et al.

Cancer Gene Therapy|June 28, 2008

ONYX-411, a conditionally replicative oncolytic adenovirus, induces cell death in anaplastic thyroid carcinoma cell lines and suppresses the growth of xenograft tumors in nude miceH V Reddi, P Madde, A J Reichert-Eberhardt, et al.

Oncogene|December 7, 2005

Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1J A Copland, L A Marlow, S Kurakata, et al.

Oncogene|March 9, 2010

Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinomaS J Cooper, H Zou, S N Legrand, et al.

The Journal of Clinical Endocrinology and Metabolism|April 17, 2013

Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trialR C Smallridge, J A Copland, M S Brose, et al.

Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:

Pageof 3

You have reached the last page of results.This site can display upto 29 results.

The Journal of Steroid Biochemistry and Molecular Biology|June 1, 1994

Design of novel antiestrogensL B Hendry, C K Chu, M L Rosser, et al.

Genes & Cancer|September 10, 2010

Expression of the PAX8/PPARγ Fusion Protein Is Associated with Decreased Neovascularization In Vivo: Impact on Tumorigenesis and Disease PrognosisH V Reddi, P Madde, L A Marlow, et al.

Neuropeptides|December 1, 1996

Molecular cloning and functional characterization of the oxytocin receptor from a rat pancreatic cell line (RINm5F)Y J Jeng, S J Lolait, Z Strakova, et al.

The Journal of Steroid Biochemistry and Molecular Biology|October 1, 1993

Inhibition of estrogen stimulated mitogenesis by 3-phenylacetylamino-2,6-piperidinedione and its para-hydroxy analogJ A Copland, L B Hendry, C K Chu, et al.

Cell Proliferation|May 29, 2007

Directed engineering of umbilical cord blood stem cells to produce C-peptide and insulinL Denner, Y Bodenburg, J G Zhao, et al.

Cancer Gene Therapy|June 28, 2008

ONYX-411, a conditionally replicative oncolytic adenovirus, induces cell death in anaplastic thyroid carcinoma cell lines and suppresses the growth of xenograft tumors in nude miceH V Reddi, P Madde, A J Reichert-Eberhardt, et al.

Oncogene|December 7, 2005

Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1J A Copland, L A Marlow, S Kurakata, et al.

Oncogene|March 9, 2010

Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinomaS J Cooper, H Zou, S N Legrand, et al.

The Journal of Clinical Endocrinology and Metabolism|April 17, 2013

Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trialR C Smallridge, J A Copland, M S Brose, et al.

Pageof 3